HSBC upgraded Eli Lilly (LLY) to Hold from Reduce with a $700 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Stock (NVO) Slides on Rival Weight Loss Pill News
- Eli Lilly (LLY) Prepares for Weight Loss Pill Approval After Late-Stage Clinical Trial
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Closing Bell Movers: MongoDB jumps nearly 30% after beat and raise
- Eli Lilly & Co’s Orforglipron Shows Promising Phase III Trial Results, Boosting Buy Rating